XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments which are generally determined based on the decision-making structure of Bausch + Lomb and the grouping of similar products and services: (i) Vision Care, (ii) Pharmaceuticals and (iii) Surgical.
•The Vision Care segment consists of: (i) sales of contact lenses that span the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses, and (ii) sales of contact lens care products and OTC eye drops, eye vitamins and mineral supplements that address various conditions, including eye allergies, conjunctivitis and dry eye.
•The Pharmaceuticals segment consists of sales of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and the treatment of a number of eye conditions, such as glaucoma, ocular hypertension and retinal diseases.
•The Surgical segment consists of sales of medical devices and technologies for the treatment of cataracts, cornea, vitreous and retinal eye conditions and includes IOLs and delivery systems, phacoemulsification and vitrectomy equipment and other surgical instruments and devices.
Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements were not material to the periods presented. Prior period presentations of segment revenues and profits have been conformed to the current segment reporting structure.
Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
Segment Revenues and Profit
Segment revenues and profits for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended June 30,Six Months Ended June 30,
(in millions)2023202220232022
Revenues:  
Vision Care$646 $588 $1,233 $1,148 
Pharmaceuticals194 169 355 324 
Surgical195 184 378 358 
Total revenues$1,035 $941 $1,966 $1,830 
Segment profit:  
Vision Care$167 $145 $321 $304 
Pharmaceuticals68 52 114 92 
Surgical9 11 20 26 
Total segment profit244 208 455 422 
Corporate(128)(89)(275)(182)
Amortization of intangible assets(56)(64)(113)(129)
Other expense, net(17)1 (26)(1)
Operating income43 56 41 110 
Interest income5 1 8 1 
Interest expense (Note 4)(58)(44)(108)(64)
Foreign exchange and other(9)14 (15)9 
(Loss) income before provision for income taxes$(19)$27 $(74)$56 
Revenues by Segment and by Product Category
Revenues by segment and product category were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended June 30,
(in millions)20232022202320222023202220232022
Pharmaceuticals$1 $1 $133 $113 $— $— $134 $114 
Devices215 213 — — 193 180 408 393 
OTC421 366 — — — — 421 366 
Branded and Other Generics7 7 61 55 — — 68 62 
Other revenues2 1 — 1 2 4 4 6 
$646 $588 $194 $169 $195 $184 $1,035 $941 
Six Months Ended June 30,
20232022202320222023202220232022
Pharmaceuticals$2 $2 $240 $219 $— $— $242 $221 
Devices439 427 — — 375 352 814 779 
OTC774 702 — — — — 774 702 
Branded and Other Generics14 13 115 103 — — 129 116 
Other revenues4 4 — 2 3 6 7 12 
$1,233 $1,148 $355 $324 $378 $358 $1,966 $1,830 
Certain reclassifications to product categories have been made and are reflected in the table above. These reclassifications are not material.
The top ten products/franchises represented 57% and 58% of total revenues for the six months ended June 30, 2023 and 2022, respectively.
Geographic Information
Revenues are attributed to a geographic region based on the location of the customer and were as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
(in millions)2023202220232022
U.S. and Puerto Rico$466 $430 $870 $816 
China89 76 163 158 
France62 56 118 111 
Japan46 47 94 97 
Germany40 33 82 76 
United Kingdom29 27 58 54 
Canada27 24 53 46 
Russia26 30 50 47 
Spain24 22 44 41 
Italy22 21 42 41 
Mexico15 14 31 25 
Poland14 12 26 23 
South Korea12 11 23 22 
Australia11 9 21 17 
Other152 129 291 256 
$1,035 $941 $1,966 $1,830 
Major Customers
No individual customer accounted for 10% or more of total revenues.